The effects and efficacy of sotolaxib (AMG510)

Sotoracib (AMG510) is a targeted drug used to treat non-small cell lung cancer (NSCLC). It is a KRAS G12C mutation inhibitor and is mainly used to treat advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. KRAS G12C mutation is one of the most common lung cancer mutations, accounting for approximately 13% of NSCLC. This mutation leads to abnormal activation of signaling pathways, promoting the growth and survival of tumor cells. Sotorasiib blocks this abnormal signaling pathway by inhibiting the activity of KRAS G12C mutant protein.

Normally, GTP binds to KRAS, activating the protein and promoting effectors of the MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. The KRAS G12C mutation impairs the hydrolysis of GTP in its active form. Sotorasiib binds to the cysteine u200bu200bresidue in the KRAS G12C mutation, leaving the protein in an inactive state. The cysteine u200bu200bresidue targeted by sotoraxib is not present in wild-type KRAS, which prevents off-target effects. Sotorasiib is the first drug approved to target the KRAS G12C mutation. It can specifically bind and inhibit the activity of KRAS G12C mutant protein, thereby interfering with the proliferation and viability of cancer cells. Combining sotoracib with chemotherapy drugs can enhance the therapeutic effect. Studies have shown that overall survival and progression-free survival were significantly longer in patients treated with sotorasib in combination with chemotherapy.

Sotoraxib is an example of an individualized treatment strategy. Because the drug is only effective against tumors with KRAS G12C mutations, genetic testing is needed to determine whether a patient is a candidate for sotoraxib. During treatment with sotorasiib, its duration of action is moderate when taken daily. Patients should be counseled about the risks of hepatotoxicity, interstitial lung disease, and pneumonia; and to avoid breastfeeding during treatment and for 1 week after the last dose.